Impact of renin - angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: A meta-analysis

International Journal of Clinical Practice

Volumn 69, Issue 6, 2015, Pages 674-681

  Ye, R ^a   Hu, Y ^a   Yao, A ^b   Yang, Y ^a   Shi, Y ^a   Jiang, Y ^a   Zhang, Junjian ^a  

^a WUHAN UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; RENIN INHIBITOR; ANTIHYPERTENSIVE AGENT;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG TARGETING; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CHINA; COGNITION DISORDERS; DISEASE COURSE; DRUG EFFECTS; HYPERTENSION; PHYSIOLOGY;

ALZHEIMER DISEASE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHINA; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; INCIDENCE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84930033259     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12626     Document Type: Article

References (34)

1. Sperling RA, Aisen PS, Beckett LA, et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
2. O'Caoimh R, Kehoe PG, Molloy DW,. Renin angiotensin aldosterone system inhibition in controlling dementia-related cognitive decline. J Alzheimers Dis 2014; 42 (Suppl. 4): 575-86.
3. Launer LJ, Ross GW, Petrovitch H, et al., Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55.
4. Zhao W, Wang J, Ho L, et al., Identification of antihypertensive drugs which inhibit amyloid-beta protein oligomerization. J Alzheimers Dis 2009; 16: 49-57.
5. Hajjar I, Catoe H, Sixta S, et al., Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol Series A Biol Sci Med Sci 2005; 60: 67-73.
6. Hajjar I, Rodgers K,. Do angiotensin receptor blockers prevent Alzheimer's disease? Curr Opin Cardiol 2013; 28: 417-25.
7. Moher D, Liberati A, Tetzlaff J, et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-41.
8. Stang A,. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-5.
9. Higgins JP, Altman DG, Gotzsche PC, et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
10. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
11. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
12. Bucher HC, Guyatt GH, Griffith LE, Walter SD,. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.
13. Ohrui T, Matsui T, Yamaya M, et al., Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-50.
14. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM,. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699-708.
15. Li NC, Lee A, Whitmer RA, et al., Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
16. Khachaturian AS, Zandi PP, Lyketsos CG, et al., Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686-92.
17. Yasar S, Xia J, Yao W, et al., Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 2013; 81: 896-903.
18. Qiu WQ, Mwamburi M, Besser LM, et al., Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis 2013; 37: 421-8.
19. Hsu CY, Huang CC, Chan WL, et al., Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population-a nationwide cohort study. Circ J 2013; 77: 405-10.
20. Hajjar IM, Keown M, Lewis P, Almor A,. Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observational study. Am J Alzheimers Dis Other Demen 2008; 23: 77-83.
21. Kume K, Hanyu H, Sakurai H, et al., Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 2012; 12: 207-14.
22. Li W, Zhang JW, Lu F, et al., Effects of telmisartan on the level of Abeta1-42, interleukin-1beta, tumor necrosis factor alpha and cognition in hypertensive patients with Alzheimer's disease. Zhonghua Yi Xue Za Zhi 2012; 92: 2743-6.
23. Ohrui T, Tomita N, Sato-Nakagawa T, et al., Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-5.
24. Soto ME, van Kan GA, Nourhashemi F, et al., Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la Maladie d'Alzheimer Francais cohort. J Am Geriatr Soc 2013; 61: 1482-8.
25. Ashby EL, Kehoe PG,. Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. Expert Opin Investig Drugs 2013; 22: 1229-42.
26. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al., Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013; 31: 1073-82.
27. Austin BP, Nair VA, Meier TB, et al., Effects of hypoperfusion in Alzheimer's disease. J Alzheimers Dis 2011; 26 (Suppl. 3): 123-33.
28. Kehoe PG, Miners S, Love S,. Angiotensins in Alzheimer's disease-friend or foe? Trends Neurosci 2009; 32: 619-28.
29. Zou K, Yamaguchi H, Akatsu H, et al., Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007; 27: 8628-35.
30. AbdAlla S, Langer A, Fu X, Quitterer U,. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. Int J Mol Sci 2013; 14: 16917-42.
31. Sink KM, Leng X, Williamson J, et al., Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Int Med 2009; 169: 1195-202.
32. Joas E, Backman K, Gustafson D, et al., Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012; 59: 796-801.
33. Chang-Quan H, Hui W, Chao-Min W, et al., The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 2011; 65: 1295-305.
34. Alzheimer's A,. Alzheimer's disease facts and figures. Alzheimers Dement 2014; 2014 (10): e47-92.